LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

LivaNova PLC

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.

SeaSpine Holdings Corporation

LivaNova develops medical devices and therapies focused on conditions affecting the head and heart, self-described as providing breakthrough treatments to improve and sustain the quality of life.

Metric
Company Name	LivaNova PLC	SeaSpine Holdings Corporation
Symbol	LIVN	SPNE
MSH ID	COM:LIVANOVA	COM:SEASPINE
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Medical - Devices	Medical - Devices
Country	GB	US
Stage
Employee Count	2.90K	523
Website	livanova.com	seaspine.com
LinkedIn
Founders

Metric
Market Cap	2.71B
Enterprise Value
Monthly Web Traffic		1.86K
Web Traffic Growth		-0.23
Valuation
Raised Capital

Metric
Revenue	1.15B	191.45M
Revenue (LTM)
Revenue (NTM)
Gross Profit	785.45M	114.59M
EBITDA	159.81M	-55.45M
Operating Income	98.95M	-60.98M
Net Income	17.55M	-54.35M
EPS	0.33	-1.62
Diluted EPS	0.32	-1.62
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.68	0.60
Operating Profit Margin	0.00	-0.32
EBITDA Margin	0.14	-0.29
Net Profit Margin	0.02	-0.28
Return on Equity	0.01	-0.22
Return on Assets	0.01	-0.14
Return on Capital Employed	0.00	-0.19

COM:LIVANOVA

LivaNova

Last Close

51.70

22/11 21:00

Market Cap

2.71B

Beta: -

Volume Today

389.26K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	878.76	-7.67
P/B Ratio	2.15	1.29
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.92
EV Multiple	215.18	-1.35

Metric
Days Sales Outstanding	70.30	81.67
Days Payables Outstanding	64.81	98.11
Days Inventory Outstanding	148.21	343.32
Operating Cycle	212.72	412.40
Cash Conversion Cycle	139.24	315.99
Asset Turnover	0.49	0.51

Metric
Operating Cash Flow	74.91M	-33.51M
Free Cash Flow	39.93M	-59.55M
Cash Flow to Debt	0.20	-4.14
Operating Cash Flow/Sales	0.10	-0.18
Free Cash Flow Yield	0.00

Metric
Cash & Equivalents	577.87M	83.11M
Accounts Receivable	-28.86M	-7.93M
Inventory	147.89M	72.30M
Goodwill	782.94M	84.59M
Debt to Capitalization	0.35	0.03
Debt to Assets	0.26	0.12
Current Ratio	3.23	3.18
Quick Ratio	2.94	2.25

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.04	0.06
R&D to Revenue	0.17	0.10
SG&A to Revenue		0.22